Creating Value Through Acquisition and Growth
AffaMed Therapeutics is looking for additional opportunities in the biopharma and healthcare market to expand our commercial portfolio. We are committed to addressing the medical needs of underserved patients and the physicians who treat them. With proven experience and a talented management team supported by the financial strength of leading investors, AffaMed is developing therapeutic solutions that create value for patients and stakeholders alike.
Please contact us to discuss possible partnership opportunities.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Its product pipeline candidates are designed to provide differentiated drug delivery solutions that reduce the complexity and burden of the current standard of care by creating sustained release alternatives. Ocular Therapeutix intends to develop a product portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing.
VistaGen Therapeutics, Inc. is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets.
Under the management philosophy "contribute to society through high-quality, innovative pharmaceutical products" and "serve society through our employees", Kissei Pharmaceutical Co., Ltd. provides unique innovative pharmaceutical products as a drug discovery and R&D-oriented company for patients in the world with a special focus on urology, renal diseases dialysis, diabetes, gastroenterology and rare diseases.
SIFI is a leading ophthalmic company, headquartered in Italy, focusing on eye care since 1935. SIFI develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic diseases. SIFI is committed to improve patients' quality of life through its R&D efforts, exporting products to more than 20 countries worldwide with commercial operations in Italy, Spain, France, Romania, Mexico and Turkey. Since 2015 SIFI is backed by 21 Invest, a private equity firm founded by Alessandro Benetton.